financetom
Business
financetom
/
Business
/
Cathie Wood Sells Tesla Stock As Chinese Rivals Gain Ground — Ark Dumps Palantir Amid Privacy Concerns
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Cathie Wood Sells Tesla Stock As Chinese Rivals Gain Ground — Ark Dumps Palantir Amid Privacy Concerns
Jun 2, 2025 6:53 PM

On Monday, Cathie Wood-led Ark Invest made significant trades, notably offloading shares of Tesla Inc ( TSLA ). and Palantir Technologies Inc. ( PLTR ) .

The Tesla Trade: Ark Invest sold 1,594 shares of the Elon Musk-led company. For the day, Tesla shares closed at $342.69, making the trade, carried out through the ARK Innovation ETF ( ARKK ) , worth $546,247.

This move comes as Tesla faces stiff competition from Chinese electric vehicle rivals, which reported strong delivery numbers for May. Tesla’s competitors, including BYD, Li Auto, Nio, and Xpeng, saw sales growth in China last month, putting pressure on Tesla’s market position.

The PLTR Trade: Ark Invest also offloaded 17,467 shares of Palantir Technologies ( PLTR ). This decision comes amidst concerns over privacy and potential misuse of personal data. As reported by Benzinga, the Trump administration has been discreetly working with Palantir ( PLTR ) to gather personal data of American citizens from various federal agencies. Despite these concerns, former hedge fund manager Martin Shkreli expressed bullish views on Palantir ( PLTR ) but cautioned investors about the stock's inherent volatility in an interview.

The Ark trade was made through ARKK. On Tuesday, Palantir ( PLTR ) stock closed at $132.04. The sale of shares was worth $2.31 million.

Other Key Trades:

Ark Invest purchased 25,447 shares of eToro Group Ltd. (ETOR).

Ark Invest bought 51,903 shares of Illumina Inc. (ILMN).

Ark Invest sold 278,792 shares of Adaptive Biotechnologies Corp. (ADPT).

Ark Invest bought 335,140 shares of 10X Genomics Inc. (TXG) through multiple ETFs.

Ark Invest sold 55,419 shares of Roblox Corp. (RBLX).

Benzinga's Edge Stock Rankings indicate that Tesla scores high on Momentum, Growth, Quality And Value. Find out how Palantir ( PLTR ) compares.

Read Next: 

Trump Administration Shuts Down $66 Million Food Stamp Fraud And Bribery Scheme, Arrests USDA Employee And 5 Others

This story was generated using Benzinga Neuro and edited by Shivdeep Dhaliwal

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Goldman CEO's leadership criticized by ethics group at annual meeting
Goldman CEO's leadership criticized by ethics group at annual meeting
Apr 24, 2024
SALT LAKE CITY, Utah (Reuters) - The conservative-leaning National Legal and Policy Center criticized Goldman Sachs ( GS ) CEO David Solomon's leadership at the bank's annual meeting on Wednesday. Mr. Solomon's poor decision making led to substantial losses in company's retail banking division, said Luke Perlot, associate director of the NLPC's corporate integrity project. (Reporting by Saeed Azhar in...
--McKesson Keeps Quarterly Dividend at $0.62 Per Share; Payable July 1 to Shareholders of Record on June 3
--McKesson Keeps Quarterly Dividend at $0.62 Per Share; Payable July 1 to Shareholders of Record on June 3
Apr 24, 2024
11:30 AM EDT, 04/24/2024 (MT Newswires) -- Price: 530.68, Change: -1.32, Percent Change: -0.25 ...
Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism
Ascendis Pharma Gets UK Regulator's Approval for Yorvipath to Treat Hypoparathyroidism
Apr 24, 2024
11:33 AM EDT, 04/24/2024 (MT Newswires) -- Ascendis Pharma ( ASND ) said Wednesday that the UK's Medicines and Healthcare Products Regulatory Agency has granted marketing authorization for Yorvipath as a parathyroid hormone, or PTH, replacement therapy to treat adults with chronic hypoparathyroidism. The UK regulator also granted orphan drug status to Yorvipath, or palopegteriparatide, providing 10 years of market...
Bank of America shareholders reject proposal to split CEO, chair roles
Bank of America shareholders reject proposal to split CEO, chair roles
Apr 24, 2024
NEW YORK, April 24 (Reuters) - Bank of America ( BAC ) shareholders rejected a proposal to divide the CEO and chairman roles held by Brian Moynihan on Wednesday at the company's virtual annual meeting. Proxy advisers had recommend investors vote for the bank to separate the positions in an effort to improve governance. The proposal was backed by 31%...
Copyright 2023-2026 - www.financetom.com All Rights Reserved